Press Releases

19.09.2023 –  Wörwag Pharma is taking over contract manufacturer Mauermann-Arzneimittel KG with immediate effect. The Böblingen-based pharmaceutical specialist is thus investing in its own production capacities.

08.03.2022 –  An international expert panel published recommendations for diagnosis and management of diabetic neuropathy. Wörwag Pharma provides information on the current consensus recommendations for health care professionals.

17.02.2022 –  Böblingen, February 17th, 2022 – The Boeblingen-based family-owned company Wörwag Pharma invested in several strategic milestones in 2021 and successfully closed the year with a year-on-year increase in sales to 269.9 million euros. The signs continue to focus on investment and growth.

13.11.2021 –  In order to support science and research, Wörwag Pharma has awarded the 10th Fritz Wörwag Research Prize this year. The prize rewards new research findings in the field of biofactors – this year on “Biofactors in diabetes and its comorbidities“.

26.05.2021 –  Just in time for the anniversary year, Wörwag Pharma presents itself with a new logo: traditional yet innovative, rooted yet globally oriented.

04.05.2021 –  Böblingen/Lódz – German pharmaceutical company Wörwag Pharma GmbH & Co. KG announces the acquisition of Sensilab, contract manufacturer and development service provider of pharmaceuticals, in Lódz, Poland. For the first time in the 50-year history, the family-owned company is investing in its own production facility - a decisive milestone for future growth.

16.04.2021 –  Wörwag Pharma announces that Lucia Cinque will join the company as Managing Director on June 1, 2021. In the newly created role of Chief Innovation Officer (CINO), she will lead the company together with Jochen Schlindwein, CEO, and Gerhard Mayer, CFO.